Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction

Condition:   Heart Failure
Interventions:   Drug: BAY1142524;   Drug: BAY1142524;   Drug: BAY1142524;   Drug: BAY1142524;   Drug: Placebo
Sponsor:   Bayer
Not yet recruiting - verified May 2015

Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction

Condition:   Myocardial Infarction
Intervention:   Drug: Nicorandil
Sponsors:   Pusan National University Hospital;   JW Pharmaceutical
Recruiting - verified May 2015

Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial

Condition:   Percutaneous Coronary Intervention
Interventions:   Drug: Bivalirudin;   Drug: Unfractionated heparin
Sponsor:   Kaiser Permanente
Recruiting - verified May 2015

Late Reperfusion With Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction

Conditions:   Ischemic Heart Disease;   ST-segment Elevation Myocardial Infarction
Intervention:   Procedure: PCI
Sponsor:   Thomas Engstrom
Recruiting - verified May 2015

Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome

Conditions:   Cardiac Death;   Hemorrhage;   Cerebrovascular Accident;   Myocardial Infarction
Interventions:   Device: BES (biodegradable polymer biolimus-eluting stent);   Drug: Prasugel;   Drug: Clopidogrel
Sponsor:   Chonnam National University Hospital
Recruiting - verified May 2015

A Prospective, Single-Blinded, Multi-Center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System) in the Treatment of Patients With Coronary Heart Disease

Condition:   Coronary Heart Disease
Interventions:   Device: MiStentTM;   Device: TIVOLI
Sponsors:   Micell Technologies;   Hefei Life Science Medical Instruments Co. Ltd.;   Giant Med-Pharma Services Inc.;   CCRF Consulting Co., Ltd.
Not yet recruiting - verified May 2015

Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)

Condition:   Anticoagulation, Blood Thinners , Atrial Fibrillation, Bleeding, Stroke
Sponsor:   Bristol-Myers Squibb
Recruiting - verified May 2015

Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure

Condition:   Coronary Artery Disease.
Interventions:   Drug: Ivabradine;   Drug: Placebo
Sponsor:   Servier
Completed - verified May 2015

Natural History of Atherosclerosis in Real-World Patients Underwent Computed Tomography Angiography

Conditions:   Coronary Atherosclerosis;   Coronary Artery Disease;   Radiocontrast-induced Thyroid Dysfunction;   Contrast-induced Nephropathy
Interventions:   Radiation: Coronary computed tomography angiography;   Radiation: Quantitative coronary angiography
Sponsors:   Ural State Medical Academy;   Ural Institute of Cardiology;   De Haar Research Foundation
Enrolling by invitation - verified May 2015

COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

Condition:   ST Elevation Acute Myocardial Infarction
Interventions:   Drug: Exenatide;   Other: Remote Ischemic Conditioning (RIC)
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Not yet recruiting - verified March 2015

CRIC-Visceral Adiposity and Physical Fitness in Chronic Kidney Disease

Conditions:   Renal Insufficiency, Chronic;   Obesity
Sponsors:   The Cleveland Clinic;   University of Pennsylvania;   Case Western Reserve University;   University of Michigan;   University of Illinois at Chicago;   University of Maryland;   MetroHealth Medical Center
Recruiting - verified April 2015

Brilinta Taiwan Post Approval Safety Study

Condition:   Non ST-elevation Myocardial Infarction
Intervention:   Drug: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Sponsor:   AstraZeneca
Recruiting - verified May 2015

P3AMI Antiplatelet Trial

Condition:   Heart Attack
Interventions:   Drug: Prasugrel;   Drug: Clopidogrel;   Drug: ticagrelor
Sponsor:   The Royal Wolverhampton Hospitals NHS Trust
Recruiting - verified May 2015

Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease

Condition:   Coronary Artery Disease
Interventions:   Procedure: Computed tomography angiography (cardiac CT);   Procedure: Invasive coronary angiography (ICA)
Sponsor:   Charite University, Berlin, Germany
Not yet recruiting - verified May 2015

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified May 2015

The Use of Texting Messaging to Improve the Hospital-to-community Transition Period in Cardiovascular Disease Patients

Conditions:   Cardiovascular Disease;   Acute Coronary Syndrome
Intervention:   Behavioral: Txt2Prevent
Sponsors:   Simon Fraser University;   Providence Health & Services;   University of British Columbia;   McMaster University;   Canadian Institutes of Health Research  (CIHR)
Not yet recruiting - verified May 2015

Human Umbilical Cord Stroma MSC in Myocardial Infarction

Conditions:   Chronic Ischemic Cardiomyopathy;   Coronary Artery Bypass Surgery
Intervention:   Biological: stem cell transplantation
Sponsors:   Ankara University;   Hacettepe University;   Turkiye Yuksek Ihtisas Education and Research Hospital;   ATIGEN-CELL;   Dr. Sami Ulus Children's Hospital;   Yildirim Beyazit University
Recruiting - verified May 2015

A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction

Conditions:   Heart Attack;   NSTEMI
Interventions:   Biological: AMI MultiStem cells;   Other: Sham
Sponsors:   Athersys, Inc;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified May 2015

Cerebral Oxygenation in Septic Patients Using Vasopressors - the Conscious Study

Condition:   Septic Shock
Sponsor:   Karl-Andre Wian
Recruiting - verified May 2015

TandemHeart to Reduce Infarct Size (TRIS Trial)

Condition:   Acute Myocardial Infarction
Interventions:   Device: TandemHeart System;   Procedure: Percutaneous coronary intervention
Sponsor:   CardiacAssist, Inc.
Recruiting - verified May 2015

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

Conditions:   Lung Cancer;   Breast Cancer;   Prostate Cancer;   Tumors (Others);   Ovarian Cancer
Intervention:   Biological: MVA-brachyury- TRICOM
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified May 2015

Is the 4MGS a Useful Outcome Measure Post-PPCI

Condition:   Acute Myocardial Infarction
Sponsors:   Royal Brompton & Harefield NHS Foundation Trust;   Medical Research Council
Recruiting - verified May 2015

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL112;   Biological: Placebo
Sponsor:   CSL Behring
Recruiting - verified May 2015

Progression of Coronary Atherosclerosis in Asymptomatic Diabetic Subjects

Conditions:   Type 2 Diabetes;   Coronary Artery Disease
Sponsors:   British Cardiac Research Trust;   Royal Free Hospital NHS Foundation Trust;   London North West Healthcare NHS Trust;   Barnet and Chase Farm Hospitals NHS Trust;   Diabetes and Obesity Research Network;   Lund University;   Health Diagnostic Laboratory, Inc.
Recruiting - verified May 2015

Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention)

Conditions:   PRU(Platelet Reactivity Unit);   APT(Antiplatelet Therapy);   HOTPR(High on Treat Platelet Reactivity)
Intervention:   Drug: clopidogrel, ticagrelor, cilostazole
Sponsor:   Taipei City Hospital
Recruiting - verified April 2014

The GRAFT Study: Evaluation of Graft Function, Rejection and Cardiac Allograft Vasculopathy in First Heart Transplant Recipients.

Condition:   Heart Transplant Recipients
Interventions:   Procedure: OCT and coronary angiography;   Procedure: Right heart cat.;   Radiation: PET;   Procedure: Echocardiography;   Procedure: exercise test;   Other: blood samples
Sponsor:   Aarhus University Hospital Skejby
Recruiting - verified May 2015

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsor:   Bayer
Recruiting - verified May 2015

Transfusion Requirements in Cardiac Surgery III

Condition:   Disorder; Heart, Functional, Postoperative, Cardiac Surgery
Interventions:   Other: Restrictive Transfusion Strategy;   Other: Liberal transfusion strategy
Sponsor:   St. Michael's Hospital, Toronto
Recruiting - verified May 2015

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Recruiting - verified May 2015

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified May 2015

Ticagrelor in Severe Community Acquired Pneumonia

Condition:   Community Acquired Pneumonia, Severe
Interventions:   Drug: Ticagrelor;   Drug: Placebo
Sponsors:   Gordon Bernard;   AstraZeneca
Recruiting - verified May 2015

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Conditions:   Acute Ischaemic Stroke;   Transient Ischaemic Attack.
Interventions:   Drug: ticagrelor;   Drug: Acetylsalicylic acid (ASA)
Sponsor:   AstraZeneca
Recruiting - verified May 2015

Hypoglycemia (Low Blood Sugar) and the Heart

Conditions:   Hypoglycemia;   Type 2 Diabetes
Sponsor:   University of British Columbia
Recruiting - verified May 2015

To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated Vessels

Conditions:   Coronary Disease;   Coronary Artery Disease;   Coronary Restenosis
Intervention:   Device: Absorb BVS
Sponsor:   Abbott Vascular
Recruiting - verified May 2015

First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)

Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis
Intervention:   Device: Percutaneous Coronary Intervention (DREAMS) stenting
Sponsor:   Biotronik AG
Recruiting - verified May 2015

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Stroke
Interventions:   Drug: Apixaban;   Drug: aspirin
Sponsors:   Population Health Research Institute;   Bristol-Myers Squibb;   Pfizer;   Medtronic
Recruiting - verified May 2015

Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

Condition:   Surgical Procedures
Interventions:   Drug: GSK1278863;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified April 2015

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)

Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
Interventions:   Device: XIENCE V EECSS;   Device: ABSORB BVS System
Sponsor:   Abbott Vascular
Active, not recruiting - verified May 2015

Determining the Effect of Abacavir on Platelet Activation

Conditions:   HIV;   Cardiovascular Disease
Intervention:   Drug: Abacavir
Sponsor:   Bayside Health
Completed - verified May 2015

Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention

Condition:   Acute ST Segment Elevation Myocardial Infarction
Interventions:   Drug: NAC;   Drug: Saline
Sponsor:   Suleyman Demirel University
Recruiting - verified October 2014

Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients

Conditions:   Stroke,;   Embolism
Intervention:   Other: Rivaroxaban ( Xarelto, BAY59-7939)
Sponsor:   Bayer
Active, not recruiting - verified May 2015

Effects of N-acetyl Cysteine During Percutaneous Coronary Intervention

Condition:   Coronary Artery Disease
Interventions:   Drug: N-acetyl cysteine;   Drug: Saline
Sponsor:   Suleyman Demirel University
Recruiting - verified October 2014

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: rivaroxaban 2.5 mg;   Drug: rivaroxaban 15 mg;   Drug: rivaroxaban 10 mg;   Drug: aspirin (ASA);   Drug: vitamin K antagonist (VKA);   Drug: clopidogrel;   Drug: prasugrel;   Drug: ticagrelor
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer
Recruiting - verified May 2015

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention & Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute
Recruiting - verified May 2015

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Recruiting - verified May 2015

Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins

Conditions:   Cavernous Angioma, Familial;   Cerebral Cavernous Malformations;   Cerebral Cavernous Hemangioma
Intervention:   Drug: Simvastatin
Sponsors:   University of New Mexico;   National Institute of Neurological Disorders and Stroke (NINDS);   University of California, San Francisco
Recruiting - verified May 2015

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

Condition:   Peripheral Artery Disease
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsor:   AstraZeneca
Active, not recruiting - verified May 2015

Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?

Condition:   Hip Fracture
Intervention:   Drug: tranexamic acid
Sponsor:   Mayo Clinic
Active, not recruiting - verified May 2015

China PEACE-Prospective AMI Study

Condition:   Coronary Heart Disease
Sponsors:   China National Center for Cardiovascular Diseases;   Ministry of Health, China
Active, not recruiting - verified May 2015

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Condition:   Smoking Cessation
Interventions:   Drug: placebo;   Drug: varenicline tartrate;   Drug: bupropion hydrochloride;   Drug: Nicotine Replacement Therapy Patch
Sponsor:   Pfizer
Active, not recruiting - verified May 2015

Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)

Condition:   Leukemia
Intervention:   Drug: Ponatinib
Sponsors:   M.D. Anderson Cancer Center;   Ariad Pharmaceuticals
Active, not recruiting - verified May 2015

Perioperative Versus Postoperative Glycemia Control in Cardiac Surgery Patients

Conditions:   Perioperative and Postoperative Hyperglycemia;   Tight Glycemia Control
Intervention:   Procedure: Intensive glycemia control
Sponsor:   Charles University, Czech Republic
Completed - verified May 2015

Valvuloplasty Scoring Balloon Catheter First-in-Man Study

Condition:   Aortic Valve Stenosis
Intervention:   Device: AngioScore's Valvuloplasty Scoring Balloon
Sponsor:   Spectranetics Corporation
Active, not recruiting - verified May 2015

Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients

Condition:   ST Elevation Acute Myocardial Infarction
Interventions:   Drug: Injection of Cyclosporin;   Drug: Placebo;   Procedure: Echocardiography
Sponsor:   Hospices Civils de Lyon
Active, not recruiting - verified April 2015

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Condition:   Atherosclerosis
Interventions:   Drug: Canakinumab;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Active, not recruiting - verified May 2015

A Study of Early Robotic Ablation by Substrate Elimination of Ventricular Tachycardia

Condition:   Ventricular Tachycardia
Interventions:   Procedure: Robotic VT Ablation;   Other: Conventional Therapy
Sponsors:   Imperial College London;   Hansen Medical
Recruiting - verified September 2012

PROspective Multicenter Imaging Study for Evaluation of Chest Pain

Condition:   Chest Pain
Interventions:   Device: Coronary Angiography;   Device: Stress Echocardiogram;   Device: Nuclear Stress Test;   Device: Exercise Electrocardiogram
Sponsors:   Duke University;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified March 2015

CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases;   Risk Factors
Interventions:   Drug: Canagliflozin (JNJ-28431754);   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Active, not recruiting - verified May 2015

INFLACOR - Clinical and Genetic Predictors of Inflammation Related Complications After Heart Surgery

Condition:   Systemic Inflammatory Response Syndrome
Intervention:   Procedure: cardiac surgery with CPB use
Sponsors:   Medical University of Gdansk;   Ministry of Science and Higher Education, Poland
Completed - verified May 2015

Molecular and Morphologic Characterization of Circulating Endothelial Cells

Condition:   Acute Myocardial Infarction
Sponsor:   Scripps Translational Science Institute
Recruiting - verified May 2015

EndocardialVascularEndothelialGrowth Factor D(VEGF-D)Gene Therapy for the Treatment of Severe Coronary Heart Disease

Conditions:   Angina Pectoris;   Myocardial Infarction
Intervention:   Biological: VEGF-D gene transfer
Sponsors:   Kuopio University Hospital;   University of Eastern Finland
Active, not recruiting - verified May 2015

Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Myocardial Infarction;   Heart Failure
Interventions:   Drug: Beta adrenergic blockers;   Drug: Platelet inhibitors;   Drug: Statins;   Drug: ACE inhibitors and/or ARB and/or AA;   Procedure: PCI with stenting
Sponsor:   Institute of Cardiology, Warsaw, Poland
Terminated - verified May 2015

Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

Condition:   Myocardial Infarction
Interventions:   Drug: Prochymal®;   Drug: Placebo
Sponsor:   Mesoblast International Sàrl
Active, not recruiting - verified May 2015

A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study

Condition:   Myocardial Infarction
Interventions:   Drug: Everolimus Eluting Coronary Stent System;   Device: cobalt chromium balloon expandable stent ( non drug eluting stent Arm)
Sponsor:   Spanish Society of Cardiology
Completed - verified May 2015

Promoting Healthy Weight With 'Stability Skills First'

Condition:   Obesity
Intervention:   Behavioral: Behavioral weight-loss/lifestyle interventions
Sponsors:   Stanford University;   National Cancer Institute (NCI)
Completed - verified May 2015

Insulin Resistance and Atherosclerosis in Women With Lupus

Conditions:   Systemic Lupus Erythematosus;   Insulin Resistance;   Atherosclerosis
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Completed - verified May 2015


Conditions:   Coronary Artery Stenosis;   Coronary Arteriosclerosis;   Coronary Artery Disease;   Coronary Artery Restenosis;   Total Coronary Occlusion;   Stent Thrombosis;   Vascular Disease;   Myocardial Ischemia
Intervention:   Device: XIENCE V®/ XIENCE PRIME™
Sponsor:   Abbott Vascular
Completed - verified May 2015

Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease

Condition:   Graft vs Host Disease
Intervention:   Drug: Topical Dexamethasone
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2015

Frontier Registry II Bifurcation Stent System Registry

Condition:   Coronary Artery Disease
Intervention:   Device: Multi-Link Frontier Coronary Stent System
Sponsor:   Abbott Vascular
Withdrawn - verified May 2015

Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.

Conditions:   Ischemic Heart Failure;   Ischemic Heart Disease;   Ischemic Cardiomyopathy
Intervention:   Drug: Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)
Sponsor:   Genzyme, a Sanofi Company
Terminated - verified May 2015

Get CardioSmart

You're Invited